Outcome of non-functioning ACTH pituitary tumors: silent does not mean indolent.
Ki-67
Mitotic count
Pituitary tumor
Silent corticotropinoma
p53
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
accepted:
03
07
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
Silent corticotroph tumors (siACTH) represent a rare entity of pituitary tumors (PT), usually more aggressive than other PT. Few predictor factors of recurrence in the post-operative period have been proposed until now. This study aimed (1) to evaluate the clinical outcome of siACTH after surgery according to a five-tiered clinicopathological classification (2) to compare siACTH characteristics to ACTH-secreting macroadenomas (macroCD), and silent gonadotropinomas (siLH/FSH). Between 2008 and 2022, 29 siACTH out of 865 PT cases operated in one tertiary center were included. Clinical, paraclinical, histological, and surgical data were collected and compared to 25 macroCD and 143 siLH/FSH cases, respectively. The tumor grading was established according to both invasion (no = 1; yes = 2) and proliferation (no = a; yes = b). Progression-free survival was estimated using Kaplan-Meier method and log-rank test. We identified 15 (51.7%) grade 1a, 11 (37.9%) grade 2a and 3 (10.3%) grade 2b siACTH with a trend for a 7-fold-time higher risk of progression/recurrence in grade 2b as compared to 1a (p = 0.06). The repartition of tumor grades was similar between the three subgroups, however a 5.7-fold-higher risk of progression was observed in grade 1a siACTH than in grade 1a siLH/FSH (p = 0.02). Compared to siLH/FSH, higher ACTH levels may help to preoperatively identify siACTH. The five-tiered clinicopathological classification contribute to predict the risk of recurrence of operated siACTH tumors. Noteworthy, non-invasive and non-proliferative siACTH exhibit a less favorable outcomes than their siLH/FSH counterparts, which should prompt for a personalized follow up.
Identifiants
pubmed: 38995473
doi: 10.1007/s11102-024-01428-6
pii: 10.1007/s11102-024-01428-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Daly AF, Beckers A (2020) The epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am 49:347–355. https://doi.org/10.1016/j.ecl.2020.04.002
doi: 10.1016/j.ecl.2020.04.002
pubmed: 32741475
Melmed S (2020) Pituitary-Tumor Endocrinopathies. N Engl J Med 382:937–950. https://doi.org/10.1056/nejmra1810772
doi: 10.1056/nejmra1810772
pubmed: 32130815
Aflorei ED, Korbonits M (2014) Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 117:379–394. https://doi.org/10.1007/s11060-013-1354-5
doi: 10.1007/s11060-013-1354-5
pubmed: 24481996
Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72:377–382. https://doi.org/10.1111/J.1365-2265.2009.03667.X
doi: 10.1111/J.1365-2265.2009.03667.X
pubmed: 19650784
Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol 33:6–26. https://doi.org/10.1007/S12022-022-09703-7
doi: 10.1007/S12022-022-09703-7
pubmed: 35291028
Langlois F, Lim DST, Varlamov E et al (2017) Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine 58:528–534. https://doi.org/10.1007/S12020-017-1447-6
doi: 10.1007/S12020-017-1447-6
pubmed: 29043561
George DH, Scheithauer BW, Kovacs K et al (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330–1336. https://doi.org/10.1097/00000478-200310000-00005
doi: 10.1097/00000478-200310000-00005
pubmed: 14508394
Portovedo S, Neto LV, Soares P et al (2022) Aggressive nonfunctioning pituitary neuroendocrine tumors. Brain Tumor Pathol 39:183–199. https://doi.org/10.1007/S10014-022-00441-6
doi: 10.1007/S10014-022-00441-6
pubmed: 35725837
Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135. https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
Raverot G, Dantony E, Beauvy J et al (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102:3368–3374. https://doi.org/10.1210/jc.2017-00773
doi: 10.1210/jc.2017-00773
pubmed: 28651368
Lelotte J, Mourin A, Fomekong E et al (2018) Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. 178:237–246. https://doi.org/10.1530/EJE-17-0965
Asioli S, Righi A, Iommi M et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180:127–134. https://doi.org/10.1530/EJE-18-0749
doi: 10.1530/EJE-18-0749
pubmed: 30481158
Sahakian N, Appay R, Resseguier N et al (2022) Real-life clinical impact of a five-tiered classification of pituitary tumors. Eur J Endocrinol 187:893–904. https://doi.org/10.1530/EJE-22-0812
doi: 10.1530/EJE-22-0812
pubmed: 36315463
Lenders NF, Earls PE, Wilkinson AC et al (2023) Predictors of pituitary tumour behaviour: an analysis from long-term follow-up in 2 tertiary centres. Eur J Endocrinol 189:106–114. https://doi.org/10.1093/EJENDO/LVAD079
doi: 10.1093/EJENDO/LVAD079
pubmed: 37461224
Peixe C, Alexandre MI, Gomes AR et al (2023) Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese cohort of 129 patients from a tertiary pituitary center. Pituitary 26:352–363. https://doi.org/10.1007/S11102-023-01319-2
doi: 10.1007/S11102-023-01319-2
pubmed: 37072661
Guaraldi F, Zoli M, Righi A et al (2020) A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s. Clin Endocrinol (Oxf) 93:36–43. https://doi.org/10.1111/cen.14197
doi: 10.1111/cen.14197
pubmed: 32306401
Bonneville J-FF (2016) Magnetic resonance imaging of Pituitary tumors. Front Horm Res 45:97–120. https://doi.org/10.1159/000442327
doi: 10.1159/000442327
pubmed: 27003878
Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618. https://doi.org/10.1227/00006123-199310000-00008
doi: 10.1227/00006123-199310000-00008
pubmed: 8232800
Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9:847–875. https://doi.org/10.1016/S2213-8587(21)00235-7
doi: 10.1016/S2213-8587(21)00235-7
pubmed: 34687601
pmcid: 8743006
Zhang K, Shou X, Chen H et al (2021) Clinical parameters of Silent Corticotroph Adenomas with positive and negative adrenocorticotropic hormone immunostaining: a large retrospective single-center study of 105 cases. Front Endocrinol (Lausanne) 11. https://doi.org/10.3389/FENDO.2020.608691
Ioachimescu AG, Eiland L, Chhabra VS et al (2012) Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery 71:296–303. https://doi.org/10.1227/NEU.0B013E318257C1F0
doi: 10.1227/NEU.0B013E318257C1F0
pubmed: 22517250
Jahangiri A, Wagner JR, Pekmezci M et al (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17. https://doi.org/10.1227/01.NEU.0000429858.96652.1E
doi: 10.1227/01.NEU.0000429858.96652.1E
pubmed: 23685641
Castellnou S, Vasiljevic A, Lapras V et al (2020) SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect 9:243–253. https://doi.org/10.1530/EC-20-0035
doi: 10.1530/EC-20-0035
pubmed: 32101529
pmcid: 7077525
Lüdecke DK, Buchfelder M, Fahlbusch R et al (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary Tumor Registry. Eur J Endocrinol 156:203–216. https://doi.org/10.1530/EJE.1.02326
doi: 10.1530/EJE.1.02326
pubmed: 17287410
Strickland BA, Shahrestani S, Briggs RG et al (2021) Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence. J Neurosurg 135:1706–1713. https://doi.org/10.3171/2020.10.JNS203236
doi: 10.3171/2020.10.JNS203236
pubmed: 33962375
Langlois F, Lim DST, Yedinak CG et al (2018) Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary 21:32–40. https://doi.org/10.1007/S11102-017-0844-4
doi: 10.1007/S11102-017-0844-4
pubmed: 29032459
Vuong HG, Dunn IF (2023) The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis. Endocrine 82:527–535. https://doi.org/10.1007/S12020-023-03449-W
doi: 10.1007/S12020-023-03449-W
pubmed: 37462809
Goyal-Honavar A, Sarkar S, Asha HS et al (2021) A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors. Acta Neurochir (Wien) 163:3143–3154. https://doi.org/10.1007/S00701-021-04911-2
doi: 10.1007/S00701-021-04911-2
pubmed: 34181087
Jiang S, Zhu J, Feng M et al (2021) Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary 24:564–573. https://doi.org/10.1007/S11102-021-01133-8
doi: 10.1007/S11102-021-01133-8
pubmed: 33651318
Cazabat L, Dupuy M, Boulin A et al (2014) Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol (Oxf) 81:566–572. https://doi.org/10.1111/CEN.12443
doi: 10.1111/CEN.12443
pubmed: 24601912
Kasuki L, Antunes X, Coelho MCA et al (2020) Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. Clin Endocrinol (Oxf) 92:145–149. https://doi.org/10.1111/CEN.14133
doi: 10.1111/CEN.14133
pubmed: 31773787
Ben-Shlomo A, Cooper O (2018) Silent corticotroph adenomas. Pituitary 21:183–193. https://doi.org/10.1007/S11102-018-0864-8
doi: 10.1007/S11102-018-0864-8
pubmed: 29344907
Kim D, Ku CR, Park SH et al (2018) Clinical parameters to Distinguish Silent Corticotroph Adenomas from other Nonfunctioning Pituitary Adenomas. World Neurosurg 115:e464–e471. https://doi.org/10.1016/J.WNEU.2018.04.070
doi: 10.1016/J.WNEU.2018.04.070
pubmed: 29678704
Thapar K, Scheithauer BW, Kovacs K et al (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765–771. https://doi.org/10.1227/00006123-199604000-00027
doi: 10.1227/00006123-199604000-00027
pubmed: 8692397
Buckley N, Bates AS, Broome JC et al (1995) P53 protein accumulates in Cushings adenomas and invasive non-functional adenomas. J Clin Endocrinol Metab 80:4 p following 6 – 4 p following 6. https://doi.org/10.1210/JCEM.80.2.7852482
Kawashima ST, Usui T, Sano T et al (2009) P53 gene mutation in an atypical corticotroph adenoma with Cushing’s disease. Clin Endocrinol (Oxf) 70:656–657. https://doi.org/10.1111/J.1365-2265.2008.03404.X
doi: 10.1111/J.1365-2265.2008.03404.X
pubmed: 18771563
Mete O, Hayhurst C, Alahmadi H et al (2013) The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas. Endocr Pathol 24:191–198. https://doi.org/10.1007/S12022-013-9270-Y
doi: 10.1007/S12022-013-9270-Y
pubmed: 24091601
Barry S, Korbonits M (2020) Update on the Genetics of Pituitary tumors. Endocrinol Metab Clin North Am 49:433–452. https://doi.org/10.1016/J.ECL.2020.05.005
doi: 10.1016/J.ECL.2020.05.005
pubmed: 32741481
Uraki S, Ariyasu H, Doi A et al (2020) MSH6/2 and PD-L1 expressions are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma subtypes. Int J Mol Sci 21. https://doi.org/10.3390/IJMS21082831
Zhang D, Hugo W, Bergsneider M et al (2022) Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior. Eur J Endocrinol 187:49–64. https://doi.org/10.1530/EJE-21-1183
doi: 10.1530/EJE-21-1183
pubmed: 35521707
pmcid: 9248914
Neou M, Villa C, Armignacco R et al (2020) Pangenomic classification of Pituitary neuroendocrine tumors. Cancer Cell 37:123–134. e5
doi: 10.1016/j.ccell.2019.11.002
pubmed: 31883967
Wang Z, Guo X, Wang W et al (2021) UPLC-MS/MS-based Lipidomic Profiles Revealed Aberrant Lipids Associated with Invasiveness of Silent Corticotroph Adenoma. J Clin Endocrinol Metab 106:E273–E287. https://doi.org/10.1210/CLINEM/DGAA708
doi: 10.1210/CLINEM/DGAA708
pubmed: 33031533
Giustina A, Uygur MM, Frara S et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26:583–596. https://doi.org/10.1007/S11102-023-01345-0/TABLES/3
doi: 10.1007/S11102-023-01345-0/TABLES/3
pubmed: 37640885
pmcid: 10539196
Reincke M, Sbiera S, Hayakawa A et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38. https://doi.org/10.1038/NG.3166
doi: 10.1038/NG.3166
pubmed: 25485838
Perez-Rivas LG, Theodoropoulou M, Ferraù F et al (2015) The gene of the ubiquitin-specific protease 8 is frequently mutated in Adenomas causing Cushing’s Disease. J Clin Endocrinol Metab 100:E997–E1004. https://doi.org/10.1210/JC.2015-1453
doi: 10.1210/JC.2015-1453
pubmed: 25942478
pmcid: 4490309
Pękul M, Szczepaniak M, Kober P et al (2024) Relevance of mutations in protein deubiquitinases genes and TP53 in corticotroph pituitary tumors. Front Endocrinol (Lausanne) 15. https://doi.org/10.3389/FENDO.2024.1302667
Yamamoto M, Nakao T, Ogawa W, Fukuoka H (2021) Aggressive Cushing’s Disease: Molecular Pathology and its therapeutic Approach. Front Endocrinol (Lausanne) 12. https://doi.org/10.3389/FENDO.2021.650791